Clinical Trial Update: A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nifurtimox in children with Chagas disease has completed and results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chagas Disease

Drugs mentioned

• Lampit (nifurtimox)

Snippet

Sponsor: Bayer | Conditions: Chagas Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-10-29